# Long-term Safety and Efficacy of Adjunctive Brivaracetam in Chinese Patients With Uncontrolled Focal Epilepsy

> **NCT07563634** · PHASE3 · COMPLETED · sponsor: **Jiangxi Qingfeng Pharmaceutical Co. Ltd.** · enrollment: 141 (actual)

## Conditions studied

- Epilepsy, Focal

## Interventions

- **DRUG:** Brivaracetam

## Key facts

- **NCT ID:** NCT07563634
- **Lead sponsor:** Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-07
- **Primary completion:** 2024-05-21
- **Final completion:** 2025-04-29
- **Target enrollment:** 141 (ACTUAL)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07563634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07563634, "Long-term Safety and Efficacy of Adjunctive Brivaracetam in Chinese Patients With Uncontrolled Focal Epilepsy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07563634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*